Description

ISMO 20 MG (1X30)

Indications

ISMO 20 MG is primarily indicated for the management of angina pectoris, a condition characterized by chest pain due to insufficient blood flow to the heart muscle. This medication is particularly beneficial for patients experiencing chronic stable angina, helping to reduce the frequency and severity of angina attacks. It may also be prescribed for patients with coronary artery disease to improve exercise tolerance and enhance overall quality of life.

Mechanism of Action

ISMO, containing isosorbide mononitrate as its active ingredient, functions as a nitrate vasodilator. The drug works by relaxing the smooth muscle in blood vessels, leading to dilation of both arterial and venous vessels. This vasodilation decreases the workload on the heart by reducing venous return (preload) and lowering systemic vascular resistance (afterload). Consequently, this results in a decrease in myocardial oxygen demand, which alleviates the symptoms of angina and improves cardiac efficiency.

Pharmacological Properties

ISMO is characterized by its rapid absorption and onset of action. Following oral administration, isosorbide mononitrate is well absorbed from the gastrointestinal tract, with peak plasma concentrations typically reached within 1 to 2 hours. The drug has a half-life of approximately 5 hours, allowing for effective management of angina symptoms throughout the day. ISMO exhibits a high degree of bioavailability, which is not significantly affected by first-pass metabolism, making it a reliable option for patients requiring consistent therapeutic effects.

Contraindications

ISMO should not be used in patients who are hypersensitive to isosorbide mononitrate or any of its components. Additionally, it is contraindicated in individuals with severe anemia, hypotension, or those who have recently experienced a myocardial infarction. The use of ISMO is also not recommended in patients taking phosphodiesterase-5 inhibitors, such as sildenafil, as this combination can lead to significant hypotension and other cardiovascular complications.

Side Effects

Common side effects associated with ISMO may include headache, dizziness, and flushing. These effects are primarily due to the vasodilatory properties of the medication. Other potential side effects can include nausea, vomiting, and palpitations. In rare cases, patients may experience severe hypotension or syncope. It is essential for patients to report any unusual or severe side effects to their healthcare provider promptly.

Dosage and Administration

The typical starting dose of ISMO is 20 mg taken orally once daily. Depending on the patient’s response and tolerance, the dose may be adjusted by the healthcare provider. It is important to take ISMO at the same time each day to maintain stable blood levels of the medication. Patients should swallow the tablet whole with a glass of water and not crush or chew the tablet, as this may affect its efficacy.

Interactions

ISMO may interact with other medications, potentially altering its effectiveness or increasing the risk of adverse effects. Notably, concomitant use of other nitrates, antihypertensives, or alcohol can enhance the blood pressure-lowering effects of ISMO, leading to increased risk of hypotension. Additionally, as previously mentioned, the use of phosphodiesterase-5 inhibitors within 24 hours of taking ISMO is contraindicated due to the risk of severe hypotension. Patients should inform their healthcare provider of all medications they are taking, including over-the-counter drugs and supplements, to avoid potential interactions.

Precautions

Patients with pre-existing conditions such as renal or hepatic impairment, or those with a history of hypotension, should use ISMO with caution. Regular monitoring of blood pressure is advised during treatment, particularly during the initiation phase or when adjusting the dose. It is also important for patients to avoid sudden discontinuation of ISMO, as this may precipitate rebound angina or other cardiovascular events. Gradual tapering under medical supervision is recommended if discontinuation is necessary.

Clinical Studies

Clinical studies have demonstrated the efficacy of ISMO in reducing the frequency of angina attacks and improving exercise tolerance among patients with stable angina. A randomized controlled trial published in the Journal of the American College of Cardiology showed that patients treated with isosorbide mononitrate experienced a significant reduction in angina episodes compared to those receiving a placebo. Furthermore, long-term studies have indicated that ISMO can improve the overall quality of life for patients with coronary artery disease, making it a valuable addition to their treatment regimen.

Conclusion

ISMO 20 MG is an effective medication for the management of chronic stable angina, providing relief from symptoms and enhancing exercise capacity. Its mechanism of action as a nitrate vasodilator plays a crucial role in reducing myocardial oxygen demand. While ISMO is generally well-tolerated, it is essential for patients to be aware of potential side effects, contraindications, and drug interactions. Regular follow-up with healthcare providers is necessary to ensure optimal treatment outcomes and to address any concerns that may arise during therapy.